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Abstract
Findings: BMI was increased (>25) in 22% of young healthy subjects. Increased cholesterol values
(>5.0 mmol/L) were found in 23% of subjects, LDL-C (>3.0 mmol/L) in 23%, triglycerides (>1.7
mmol/L) in 11% of subjects. We found statistically significant differences in subjects' weight (p =
0.015), BMI (p = 0.023), and waist-hip ratio (WHR) (p = 0.015) in regard to their diet type; subjects
with Mediterranean diet had the lowest values compared to those on continental and mixed diet.
Significant associations were found for: LPL genetic polymorphic variant and abdominal obesity (p
= 0.013), APO epsilon4 allele and hypercholesterolemia (p = 0.003), and ESR1-TA long allele and
hypercholesterolemia (p = 0.011).
Background: Human obesity is a multifactorial syndrome influenced also by genetic factors.
Among gene variants found to be involved in body weight regulation and development of obesity,
particular attention has been paid to polymorphisms in genes associated with obesity-related
metabolic disorders. We explored the association of genetic polymorphisms of: estrogen receptor
alpha (ESR1-TA repeats); interleukin-6 (IL-6 G-174C); apolipoprotein E (APO epsilon2, epsilon3,
epsilon4); lipoprotein lipase Pvu II (LPL P+/-), with clinical variables: gender, age, body mass index
(BMI), diet type and biological variables: triglycerides, cholesterol, HDL-C, LDL-C, CRP,
homocysteine, urate, and glucose in 105 healthy young subjects (20-35 yrs) of Croatian origin.
Methods: Genotyping of IL-6, LPL was performed by PCR-RFLP, of APOE by real-time PCR, and
of ESR1 by PCR and capillary electrophoresis. Association analyses were performed of alleles and
genotypes with biological variables.
Conclusion: ESR-1, LPL, and APO E genetic polymorphic variants could represent predictive
genetic risk markers for obesity-related metabolic disorders in young healthy subjects.
Mediterranean type of diet is also an important protective factor against abdominal obesity.
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Background
Obesity has become an extensive public health concern
because its prevalence has increased to epidemic propor-
tions.
Many gene variants are involved in development of obes-
ity and body weight regulation [1-3].
The most frequently investigated gene polymorphisms are
APOE, adiponectin (ADIPOQ), angiotensin-converting
enzyme (ACE), methyltetrahydrofolate reductase
(MTHFR), IL-6, and estrogen receptors α and β (ESR1,
ESR2) [4-7].
Our study was focused on ESR1 (L-long TA repeats; S-
short TA repeats), APOE, IL-6 and LPL in young healthy
population. Estrogen appears to be involved in protection
against obesity and regulation of food intake. ESR1 is
expressed mainly by adipocytes and it lowers the lipolytic
response in subcutaneous fat by increasing the number of
antilipolytic adrenoreceptors. BMI, waist circumference
and HDL cholesterol levels have been associated with
ESR1 polymorphisms.
A long genotype group of a common thymine-adenine
(TA) dinucleotide repeat polymorphism in the regulatory
region of ESR1 has been associated with coronary artery
disease. There is also possibility that carriers of the long
repeat are marked by decreased expression of the ESR1
gene and that they have less cardiovascular protective
effects from estrogen than carriers of the short alleles [8-
10].
APOE alleles and genetic variants of IL-6 have also been
established to be factors of susceptibility to obesity [1].
Data on C-174G polymorphism of IL-6 suggest that it
affects the IL-6 transcription rate and plays a role in the
development of obesity and insulin sensitivity [11].
LPL PvuII polymorphism is associated with high choles-
terol levels and atherosclerotic cardiovascular diseases
[12,13]. In our previous investigations ACE [14] and
APOE [15-17] were confirmed to be metabolic risk fac-
tors.
In this study we tried to identify some genetic variables
associated with lipid status and obesity in young healthy
subjects.
Methods
Human subjects
A total of 105 young healthy subjects (58 female, 47
male), aged 20-35 years, participated in the study. They
completed a questionnaire on family history of cardiovas-
cular diseases, hypertension, obesity, taking medications,
smoking and diet. All participants signed informed con-
sent forms, and the study protocol was approved by Ethics
Committee. BMI was calculated as weight (kg)/height
(square meter), and WHR was calculated as the ratio of
abdomen or waist to hip circumference. Blood samples
for biochemical analyses (total cholesterol, LDL- and
HDL-cholesterol, glucose, CRP, urate) were collected after
overnight fasting and analyzed.
DNA extraction and genotyping
ESR1-TA repeats
Dinucleotide polymorphism of ESR1 was analyzed using
PCR amplification with labeled primer 5'-6-FAM-GAC
GCA TGA TAT ACT TCA CC-3' and 5' - GCA GAA TCA AAT
ATC CAG ATG-3'. PCR was performed with 25 cycles that
consisted of 2 min at 94°C, 1 min at 58°C, and 1 min at
72°C, followed by 30 min at 60°C after the last cycle. The
alleles were size-separated by capillary gel electrophoresis
using Gene Scan Fragment Analysis Software 4.0. In short,
1 μl of the product was diluted with 12 μl of deionized
formamide containing 0.5 μl GeneScan-500 ROX internal
lane standard for sizing DNA fragments. Capillary electro-
phoresis was then carried out using ABI PRISM 310
Genetic Analyzer and POP-6 that had been formulated for
applications requiring high resolution under denaturing
electrophoretic conditions [8].
IL-6 G-174C
The primers used in the PCR were: 5' TGACTTCAGCTT-
TACTCTTTGT 3' and 5' CTGATTGGAAACCTTAT TAAG 3'.
The reaction was carried out in a final volume of 50 μl
containing 1.5 mmol/l of MgCl2, 0.2 mmol/l of each
dNTP, 0.2 mmol/l of each primer, and 2.5 unit of Taq
polymerase. DNA was amplified during 35 cycles with an
initial denaturation of 10 minutes at 94°C and a final
extension of 10 min at 72°C. The cycle program consisted
of 1 minute denaturation at 94°C, 1 minute and 35 s
annealing at 55°C and 1 min extension at 72°C. PCR
products were digested with Nla III restriction enzyme at
37°C overnight and electrophoresed on a 2% agarose gel
with ethidium bromide staining.
The identified genotypes were named according to the
presence or absence of the enzyme restriction sites, so Nla
III (GG), (GC), and (CC) are homozygotes for the pres-
ence of the site (140/58 bp), heterozygotes for the pres-
ence and absence of the site (198/140/58 bp), and
homozygotes for the absence of the site (198 bp), respec-
tively [11].
LPL P+/- and APOE epsilon2, epsilon3, epsilon4
LPL P+/- was determined using PCR-RFLP and agarose gel
electrophoresis technique, as previously described in [13]
APOE genotyping was performed by applying DNA assay
that uses rapid-cycle PCR and fluorescence resonance
energy transfer (FRET) with the LightCycler. In the assay,BMC Research Notes 2009, 2:203 http://www.biomedcentral.com/1756-0500/2/203
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a 265-bp fragment of exon 4 of the APOE gene was ampli-
fied from genomic DNA. The detection probes that cover
codons 112 and 158 were 5' labeled with LC-Red 640 and
LC-Red 705, respectively [18].
Statistical analyses
Descriptive statistics were used to present all sociodemo-
graphic and clinical features of subjects. Data were given
as means +/- standard deviations (SD) and frequencies/
percents, as appropriate. Statistical analyses were per-
formed to:
1) Study the associations of sociodemographics and all
clinical features (Table 1) with metabolic parameters. The
differences between mean values of metabolic parameters
(BMI, abdominal obesity, cholesterol, LDL, HDL, triglyc-
erides, glucose, blood pressure, CRP and urate) among
different groups according to clinical features and socio-
demographics were determined using t-tests for inde-
pendent samples or analysis of variance, as appropriate.
In case of significant differences between groups, logistic
regression was performed to test for the predictors of BMI,
abdominal obesity, high cholesterol, high LDL, low HDL,
high triglycerides, glucose intolerance, hypertension,
abnormal CRP and urate. For that purpose variables
describing metabolic status (BMI, abdominal obesity,
cholesterol, LDL, HDL, triglycerides, glucose, CRP and
urate) were grouped in categories according to their nor-
mal values - described in Table 2.
2) Study the association of genetic variants with lipid sta-
tus and BMI. For that purpose variables describing meta-
bolic status (BMI, abdominal obesity, cholesterol, LDL,
HDL, triglycerides, glucose, blood pressure, CRP and
urate) were again grouped in categories as described in
Table 2. Associations of alleles, genotypes and haplotypes
with biological variables were established using
UNPHASED-3.0.10. Sex and age were used as covariates
[19,20].
The sequential Bonferroni adjustments (Holm, 1979;
Rice, 1989) were applied to correct for the effect of multi-
ple tests using SAS Release 8.02 (SAS Institute, 1999).
Results
Basic characteristics of 105 study participants are shown
in Table 1 and Table 2. Age of the subjects was 25.82 +/-
3.28 years. BMI values ranging between 25 - 30 were
found in 21.9% of subjects. Positive family history for
obesity was established in 32.4% of subjects.
Hypertriglyceridemia was detected in 11.4% of subjects.
12.4% of subjects were on Mediterranean diet. In addi-
tion, increased CRP levels were found in 9.5% of our sub-
jects, and elevated urate levels in 11.4%. Out of 105
subjects, 9 were taking medication for cardiovascular dis-
eases, 4 were taking other medications, for 5 subjects data
were missing and the rest (N = 87) were not using medi-
cations at the time of the study.
We found an association between BMI and diet type. Dif-
ferences in weight, BMI, waist measures, and WHR of sub-
jects with regard to diet type (continental, Mediterranean,
mixed type) were significant (p = 0.015; p = 0.023; p =
0.01; p = 0.015, respectively) (Table 3). Post hoc analysis
showed that mixed type of diet contributed to signifi-
cantly different weight, waist and BMI of subjects com-
pared to those having the other two types of diet, whereas
Mediterranean diet contributed to significantly different
WHR compared to subjects on the other two types of diet
(Table 3). However, logistic regression did not confirm
diet type as a predictor of abdominal obesity and BMI
(data not shown). The most favorable results in weight,
BMI, WHR measurement were established for subjects on
Mediterranean diet (as compared to continental and
mixed diet): the type of diet, as an environmental factor,
was found to have considerable impact on health of
young population. Further, analysis of association
between ESR1 genetic polymorphisms and APOE and
hypercholesterolemia is presented in Table 4. In relation
to hypercholesterolemia, a significant interaction was
found for ESR1-L allele (p = 0.011; df = 1; X2 = 6.391). Sig-
nificant association was also established between APOE4
and hypercholesterolemia (p = 0.003; df = 2; X2 = 11.46)
(Table 4). Abdominal obesity was correlated to LPL P+/-,
P+/+ genotypes (p = 0.013; df = 2; X2 = 7.794) in a signif-
icant manner (Table 5). WHR (>0.9 -M, 0.85 - F) was
found to be a good indicator or the risk for obesity among
heterozygous and homozygous subjects for LPL genotype.
Association between blood pressure and IL-6 CC geno-
type was not found to reach statistical significance (p =
0.069; df = 2; X2 = 5.326) (Table 6). Nevertheless, it was
Table 1: Sociodemographic and clinical data of subjects 
(N = 105)
Mean +/- SD
Age (yrs) 25.82 +/-3.28
Weight (kg) 73.99+/-16.09
Height (cm) 175+/-10.53
BMI (kg/m2) 23.48+/-3.81
Waist (cm) 83.61+/-12.04
Hip (cm) 103.23+/-8.32
WHR 0.81 +/- 0.8
Triglycerides (mmol/L) 1.08+/-0.55
Cholesterol (mmol/L) 4.53+/-0.96
HDL-C (mmol/L) 1.45+/-0.3
LDL-C (mmol/L) 2.59+/-0.85
CRP (mg/L) 1.34+/-1.61
CRP (mg/L) 1.34+/-1.61
Glucose (mmol/L) 5.03+/-0.45
Urate (mmol/L) 292.70+/-76.35BMC Research Notes 2009, 2:203 http://www.biomedcentral.com/1756-0500/2/203
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substantial enough to indicate an important correlation
between high blood pressure and IL-6 (CC-genotype),
which should be examined on a larger study sample.
Discussion
Genetic biomarkers have an increasing impact in labora-
tory medicine. They are currently used to predict disease
onset or disease recurrence, and to individualize treat-
ment and assess response to treatment.
We found an association between BMI and diet type. Dif-
ferences in weight, BMI, waist measures, and WHR of sub-
jects with regard to diet type (continental, Mediterranean,
mixed type) were indicative. Subjects on Mediterranean
diet had the best results with regard to BMI and WHR,
which confirmed the assumption that the type of diet
could have a substantial effect on the health of young sub-
jects. Further, association was also established between
ESR1 and APOE genetic polymorphisms and hypercholes-
terolemia. Actually, our finding was confirmed by results
of other studies [1] who found positive correlation
between APOE polymorphism and hypercholesterolemia.
Association between estrogen receptor-alpha gene poly-
morphisms and coronary artery disease with familial
hypercholesterolemia was previously reported in other
studies [21].
Table 2: Clinical and metabolic parameters of subjects (N = 105)
Feature Frequency Percent
Somatic illness No 78 74.3
Cardiovascular illness 4 3.8
Other illnesses 14 13.3
Smoking Yes 67 63.8
No 31 29.5
Medications No 87 82.9
With known effects on investigated features (Contraceptives) 9 8.6
Other medications 4 3.8
Elevated hepatic enzymes No 77 73.3
Yes 19 18.1
Diet Continental 75 71.4
Mediterranean 13 12.4
Mixed 10 9.5
Positive family history No 25 23.8
Diabetes 12 11.4
Cardiovascular disease 32 30.5
Obesity 2 1.9
More than one 34 32.4
Hypertension (>135/85 mmHg) No 79 75.2
Yes 19 18.1
BMI (kg/m2) <25 77 73.3
25.01-30 23 21.9
> 30.01 5 4.8
Abdominal obesity (WHR >90 (M), >85 (F) No 85 83.3
Yes 17 16.7
Hypertriglyceridemia (>1.7 mmol/L) No 93 88.6
Yes 12 11.4
Hypercholesterolemia (>5 mmol/L) No 81 77.1
Yes 24 22.9
HDL-C (<1.0 mmol/L) No 98 93.3
Yes 76 . 7
LDL-C (>3 mmol/L) No 81 77.1
Yes 24 22.9
Glucose levels (>6.4 mmol/L) Hypoglycemia 4 3.8
Normal 100 95.2
Hyperglycemia 1 1.0
CRP levels (mg/L) < 1 61 58.1
1-3 34 32.4
> 3 10 9.5
Elevated urate levels (>383 mmol/L) No 93 88.6
Yes 12 11.4
M - male; F - female; HDL-C - high density lipoprotein; LDL-C - low density lipoprotein cholesterol; CRP - C-reactive proteinBMC Research Notes 2009, 2:203 http://www.biomedcentral.com/1756-0500/2/203
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Complex approach includes multiple genetic markers,
gene expression, and functional protein. Such complex
approach is needed for understanding physiopathology
and etiology of metabolic disorders and cardiovascular
disease, and leads to development of biomarkers for pre-
vention of disease. Possible metabolic biomarkers that we
examined in our study are CRP and urate: we found ele-
vated levels (9.5%; 11.4%, respectively) of these meta-
bolic parameters, and similar results in young adults were
reported previously [22,23]. Recent data also suggest that
elevated serum CRP and urate levels may contribute to the
development of coronary artery disease [24]. It has been
established that men with long alleles at the ESR1 pro-
moter TA repeat have significantly more narrowed coro-
naries, larger areas of complicated lesions, and more
calcification of coronary arteries than men with short alle-
les. A recent Finnish study proposed that long-repeat car-
riers have lower expression of the ESR1 gene and less
cardiovascular protective effects from estrogen than carri-
ers of short alleles [8].
In our study, we found an association between ESR1 long
TA allele and hypercholesterolemia in young healthy sub-
jects and it could represent a possible risk factor for devel-
oping metabolic disorder and cardiovascular disease.
For genetic prediction of disease risk, it is important to
identify functional gene polymorphism in order to estab-
lish genotype-phenotype correlation. Polymorphisms can
be associated with either health (low risk predictors) or
possible development of disease (high risk predictors;
hypercholesterolemia, hypertension, obesity, metabolic
syndrome, cardiovascular disease). Adipogenesis-related
genes such as PPAR gamma and genes related to cytokines
Table 3: Differences in weight, BMI, waist and WHR of subjects with regard to their diet type
Diet ANOVA, LSD post hoc,
Continental Mediterranean Mixed p value p values (only significant)
Weight (kg) 74+/14.56 66.61+/- 15.84 86+/-23.86 F = 4.365, p = 0.015 Mixed vs. continental, MD = 12.18, p = 0.025
Mixed vs. Mediterranean, MD = 19.58, p = 0.004
BMI (kg/m2) 23.5+/-3.21 21.73+/-2.85 26.15+/-7.31 F = 3.915, p = 0.023 Mixed vs. continental, MD = 2.65, p = 0.039
Mixed vs. Mediterranean, MD = 4.42, p = 0.006
Waist (cm) 83.65+/-11.04 76.77+/-10.83 92.1+/-17.37 F = 4.803, p = 0.01 Mixed vs. continental, MD = 8.45, p = 0.036
Mixed vs. Mediterranean, MD = 15.33, p = 0.003
WHR 0.81+/-0.07 0.76+/-0.08 0.86+/-0.09 F = 4.421, p = 0.015 Mediterranean vs. continental, MD = -0.05, p = 0.042
Mediterranean vs. mixed, MD = -0.095, p = 0.004
MD = mean difference
Table 4: Association of ESR1 and APOE genetic polymorphisms and hypercholesterolemia
Cholesterol < 5 mmol/L Cholesterol > 5 mmol/L OR CI Test p value
ESR1* Alleles S 87 14 1 1-1 X2 = 6.391
L 77 30 2.421 1.242-4.72 df = 1
p = 0.011
Genotypes SS 22 3 1 1-1 X2 = 7.147
LS 43 8 1.364 0.3288-5.661 df = 2
LL 17 11 4.745 1.141-19.73 p = 0.028
APOE** Alleles ε22 1 1 1 1 - 1 X 2 = 11.46
ε3 123 32 5.463 0.6664-44.79 df = 2
ε4 14 11 16.5 1.366-199.2 p = 0.003
Genotypes 22 2 0 1 1-1 X2 = 14.98
23 15 0 8.413e-006 8.413e-006-8.413e-006 df = 4
p = 0.004
24 2 1 1.285e+008 2.495e+007-6.62e+008
33 48 11 5.891e+007 2.27e+007-1.529e+008
34 12 10 2.1424+0088 7.876e+007-5.825e+008
APOE = apolipoprotein E
ESR1 = estrogen receptor alpha
* Means+/-SD of SS, LS and LL were 4.2+/-0.9; 4.56+/-0.97; 4.81+/-0.89, respectively
** Means+/-SD of 22, 23, 24, 33 and 34 were 3.65+/-0.92; 3.89+/-0.58; 3,83+/-1.44; 4,51+/-0.74; 4.51+/-0.95, respectivelyBMC Research Notes 2009, 2:203 http://www.biomedcentral.com/1756-0500/2/203
Page 6 of 7
(page number not for citation purposes)
such as IL-6 and lipid metabolism including LPL have also
been associated to the weight lowering outcome induced
by hypocaloric diets [25]. Efforts to reduce cholesterol
level in order to prevent coronary heart disease have led to
declined mortality. However, new information in this
regard have recently been recorded in western countries: a
decreasing trend in HDL cholesterol and increasing trends
in obesity and triglycerides [26].
In literature, correlation between LPL polymorphisms and
obesity has remained controversial; however, we found
evidence of this association in our study. Actually, pres-
ence of LPL P+/-, P+/+ genotypes that we investigated in
our study might, as a predictive risk factor related to obes-
ity-related metabolic disorder, indicate the need for indi-
vidualized diet adjustments.
A study reported previously [27] evaluated the role of IL-
6-174G>C polymorphism in the risk of developing meta-
bolic alterations in people with excessive body weight.
Their data demonstrated that the occurrence of C allele of
IL-6-174G>C gene polymorphism in people with exces-
sive body weight was accompanied by increased risk of
developing obesity-related metabolic disorders, especially
insulin resistance.
Regardless of age and gender, subjects with IL-6 C and
PPAR gamma variants had lower BMI and plasma triglyc-
eride levels than those carrying only one of these variants.
Thus, it might be possible that IL-6 gene polymorphism
alone has none or only slight effects; its effects may be
apparent only in the presence of a factor like PPAR gamma
[4]. The influence of interleukin-6 G-174C gene polymor-
phism on coronary artery disease, cardiovascular compli-
cations and mortality in dialysis patients was described in
a previously reported study. Their results suggest that IL-6
gene G-174C polymorphism is associated with the inci-
dence of cardiovascular events and mortality in chronic
dialysis patients [28]. Although this indicates an impor-
tant correlation between high blood pressure and IL-6
genotype, larger studies are needed to confirm this signif-
icance.
Conclusion
Results of examining correlation between weight, BMI
and WHR and continental, Mediterranean and mixed diet
showed optimal values in subjects on Mediterranean diet.
Statistically significant correlation was detected between
ESR1 long allele and total cholesterol. We also found sta-
tistically significant associations of APOE 2/3 and APOE3/
4 genotypes with lowered and increased cholesterol levels,
Table 5: LPL genotyping results that indicate a risk associated with abdominal obesity
WHR
<0.9 (M); <0.85 (F)
WHR
>0.9 (M); >0.85 (F)
OR CI Test
p value
Alleles P- 90 18 1 1-1 X2 = 1.158
P+ 68 22 0.6641 0.203-2.18 df = 1
LPL p = 0.272
Genotypes P-/- 26 2 1 1-1 X2 = 7.794
P-/+ 38 14 0.1057 0.01-0.86 df = 2
P+/+ 15 4 0.28 0.023-3.37 p = 0.013
LPL = lipoprotein lipase
OR = Odds ratio
CI = confidence interval
* Means+/-SD of P-/-, P-/+ and P+/+ were 0.83+/-0.07; 0.79+/-0.08; 0.79+/-0.08, respectively
Table 6: Association of IL-6 genetic polymorphisms and blood pressure
BP < 135/85 BP > 135/85 OR CI Test
p value
IL-6 Alleles C 95 20 1 1-1 X 2 = 0.952
df = 1
G 71 10 1.495 0.78-2.86 p = 0.329
Genotypes CC 30 9 1 1-1 X 2 = 5.326
CG 35 2 5.25 1.05-26.21 df = 2
GG 18 4 1.35 0.363-5.03 p = 0.069
BP = blood pressure
OR = Odds ratio
CI = confidence intervalBMC Research Notes 2009, 2:203 http://www.biomedcentral.com/1756-0500/2/203
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respectively. Statistically significant association was
observed between LPL P+/- polymorphism and abdomi-
nal obesity. These three polymorphisms indicate an asso-
ciation with traits that characterize lipid status and
obesity.
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